Treating bone loss ups survival for breast cancer patientsJune 6, 2022ASCO Breast CancerBreast CancerMetastatic Breast Cancer
Pembrolizumab before surgery improves survival in early triple negative breast cancerJune 5, 2022ASCO Breast CancerBreast CancerMetastatic Breast Cancer
New treatment outperforms chemo in HER2-low breast cancerJune 5, 2022ASCO Breast CancerBreast CancerMetastatic Breast Cancer
New treatment meets unmet need in breast cancerJune 5, 2022ASCO Breast CancerBreast CancerMetastatic Breast Cancer
‘Unlimited’ cancer costs: The Medicare Part D dilemmaMay 31, 2022Practice ManagementBreast CancerMetastatic Breast Cancer
Time-restricted eating may reduce CVD risk after breast cancerMay 31, 2022Breast CancerPatient & Survivor CarePreventive CareMixed Topics
Quadruple-negative breast cancer associated with poorest outcomesMay 17, 2022Metastatic Breast CancerBreast Cancer
Mastectomy may not be necessary for young breast cancer patientsMay 16, 2022Metastatic Breast CancerBreast Cancer
Twenty years and counting: Tamoxifen’s lasting improvement in breast cancerMay 11, 2022Metastatic Breast CancerBreast Cancer
Uninformed breast cancer patients are making treatment decisionsMay 10, 2022Metastatic Breast CancerBreast Cancer
Breast cancer test recommended for extended endocrine therapyMay 9, 2022Metastatic Breast CancerBreast Cancer
